NightHawk Biosciences, Inc. (NHWK)

NYSEAMERICAN: NHWK · IEX Real-Time Price · USD
1.29
+0.05 (3.71%)
Dec 2, 2022 3:59 PM EST - Market closed
3.71%
Market Cap 31.82M
Revenue (ttm) 6.92M
Net Income (ttm) -44.85M
Shares Out 25.61M
EPS (ttm) -1.42
PE Ratio n/a
Forward PE n/a
Dividend n/a
Ex-Dividend Date n/a
Volume 34,507
Open 1.3
Previous Close 1.24
Day's Range 1.24 - 1.3
52-Week Range 1.17 - 4.35
Beta 0.33
Analysts Buy
Price Target 12.88 (+901.6%)
Earnings Date Nov 16, 2022

About NHWK

NightHawk Biosciences, Inc., an integrated biopharmaceutical company, engages in the development of immune therapies and vaccines. The company's therapies are used to modulate the immune system against various diseases, including cancer and infectious diseases. Its gp96 platform, including ImPACT, an allogenic cell-based, T-cell-stimulating platform that functions as an immune activator to stimulate and expand T-cells; and ComPACT, which delivers antigen driven T-cell activation and specific co-stimulation in a single product. The company devel... [Read more]

Industry Biotechnology
IPO Date Jul 24, 2013
CEO Jeffrey Wolf
Employees 49
Stock Exchange NYSEAMERICAN
Ticker Symbol NHWK
Full Company Profile

Financial Performance

In 2021, NHWK's revenue was $2.11 million, a decrease of -28.33% compared to the previous year's $2.95 million. Losses were -$35.07 million, 34.6% more than in 2020.

Financial Statements

Analyst Forecast

According to 8 analysts, the average rating for NHWK stock is "Buy." The 12-month stock price forecast is 12.88, which is an increase of 901.56% from the latest price.

Price Target
$12.88
(901.56% upside)
Analyst Consensus: Buy
Stock Forecasts

News

NightHawk Biosciences Provides Third Quarter 2022 Business Update

DURHAM, N.C., Nov. 14, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the i...

2 weeks ago - GlobeNewsWire

Nighthawk Biosciences' Scorpion Subsidiary Announces Grand Opening of its San Antonio Facility

DURHAM, N.C., Oct. 21, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the i...

1 month ago - GlobeNewsWire

NightHawk Biosciences Announces Buildout of Advanced Biosafety Level 2 (BSL-2) Laboratory

Further Enhances Research Capabilities in Infectious Disease and Biodefense Further Enhances Research Capabilities in Infectious Disease and Biodefense

3 months ago - GlobeNewsWire

Why NightHawk Biosciences Stock Is Soaring

NightHawk Biosciences Inc (AMEX:NHWK) shares are trading higher Monday after the company said it would fund development of a monkeypox vaccine.

3 months ago - Benzinga

NightHawk Biosciences Provides Second Quarter 2022 Business Update

DURHAM, N.C., Aug. 10, 2022 (GLOBE NEWSWIRE) -- NightHawk Biosciences (NYSE American: NHWK), a fully-integrated biopharmaceutical company focused on developing first-in-class therapies to modulate the i...

3 months ago - GlobeNewsWire

Heat Biologics Completes Name Change to NightHawk Biosciences; Trading to Commence Under “NHWK” Effective at the Mark...

DURHAM, N.C., May 03, 2022 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. / NightHawk Biosciences (NYSE American: HTBX; NHWK), a fully integrated biopharmaceutical company focused on developing first-in-class...

7 months ago - GlobeNewsWire

Heat Biologics (“NightHawk Biosciences”) Completes Acquisition of Elusys Therapeutics

Elusys becomes wholly-owned biodefense subsidiary of NightHawk

7 months ago - GlobeNewsWire

Heat Biologics Announces Planned Name Change to NightHawk Biosciences, Reflecting Company's Evolution, Therapeutic Pi...

Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, available for replay at Nighthawkbio.com Key Corporate Updates Announced Via Livestream Event from Manhattan, Kansas, availab...

7 months ago - GlobeNewsWire